Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Belgium, Franciaország, Lengyelország, Németország, Portugália és Spanyolország61 helyszín, 6 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT07890454
- EU 2026-526221-18-00
- U1111-1332-8880
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 6000 fő, tervezett
- Kezdés
- 2026. okt. 28.
- Várható befejezés
- 2027. dec. 28.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- IIV-HD (standalone)
- NVXC19 (EU licensed, standalone)
- IIV-HD + NVXC19 combination
- Placebo, normal saline
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Aged 60 years or older on the day of inclusion
- Informed consent form has been signed and dated
- Able to attend all scheduled visits and to comply with all study procedures
- Participant must be able to receive an injection in the deltoid muscle of both arms
- Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
- Aged 60 years or older on the day of inclusion
- Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
- Non-childbearing potential (i.e., post-menopausal for at least 1 year or surgically sterile)
- lnformed consent form has been signed and dated
- Able to attend all scheduled visits and to comply with all study procedures
- Participant must be able to receive an injection in the deltoid muscle of both arms
- Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine
Ki nem vehet részt
- Known/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
- Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
- Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
- Any vaccine given within 4 weeks before or within 4 weeks after study intervention
- Previous vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
- Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
- Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
- Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved
- History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
- Personal or family history of Guillain-Barré syndrome
- Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
- Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
- Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.
A teljes eredeti leírásKevesebb
Study details include:
* The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01
A vizsgálat 2 csoportja
- Group 1, IIV-HD and EU-licensed NVXC19Már használt kezelés, összehasonlításként
IIV-HD and NVXC19 co-administered in opposite deltoid muscles
Kezelés: IIV-HD (standalone) és NVXC19 (EU licensed, standalone)
- Group 2, IIV-HD + NVXC19 combination and placeboA vizsgált kezelés
IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles
Kezelés: IIV-HD + NVXC19 combination és Placebo, normal saline
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
- A regiszteradat frissítve
- 2026. november 13.